RTTNews BiotechDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 23:50:14(美东 11:50)·⟳ 抓取 23:53:29 +3m15s·⚡ 决策 10-20 23:55:14 +1m45s·7.0 天前
翰森制药与罗氏达成超155亿美元ADC战略合作，4亿美元首付款，但利好已在港股当日涨8.3%充分兑现
该消息为2026-10-19晚间港交所公告+路透首发的明牌利好，直接、唯一实质受益标的翰森制药(3692.HK)已于10月20日港股交易日放量(量比4.28倍)收涨8.32%、盘中一度涨超9%，市场已在唯一流动性主市场完成当日重定价；当前(港股盘后)已无法以反应前价格介入，次日开盘追高面临明牌利好高开低走风险。OTC粉单HNSPF零成交不可交易，罗氏体量不受影响，A股无母公司直接标的，无具备正期望的可执行载体。
📄 原文RTTNews Biotech↗ 原文
Hansoh Pharma Inks $15 Bln-Plus ADC Deal With Roche; Stock Up
Hansoh Pharmaceutical Group Co., Ltd. (HNSPF), a China-based pharmaceutical company, has entered into a strategic colla…
不做 翰森制药集团有限公司（03692.HK）
明牌利好已price-in：消息10月19日晚港交所公告+路透首发，10月20日唯一流动性主市场已放量(量比4.28倍)收涨8.32%、盘中涨超9%完成重定价；港股现已收盘，次日开盘追高为隔夜明牌，易高开低走且无反应前价位，风险收益比不足。OTC粉单HNSPF零成交不可执行，罗氏不受影响，A股无直接标的，故不做多。
不做 翰森制药(OTC粉单)（HNSPF.US）
OTC Markets粉单，4.25美元无成交、流动性枯竭，买卖价差与成交不可靠，属结构上不可执行载体。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
翰森-罗氏超155亿美元ADC授权是真实重大利好(4亿美元首付+里程碑)，但消息10月19日晚已公告，翰森港股10月20日已放量大涨8.32%充分定价，此刻(港股收盘、仅美股盘中)只剩不可交易的零成交OTC粉单，无未被定价的可执行入场点，回避。
消息传播链
- 路透2026-10-19 18:01北京报道翰森与罗氏超150亿美元交易；同日晚翰森发布港交所公告，消息在港股次日(10-20)开盘前已完全公开
- 翰森制药官方披露战略合作及许可协议全部条款，为一手披露源
- 2026-10-20 16:08 +08:00市场反应futu行情非一手翰森3692.HK 10月20日开盘32.6高开、盘中最高34.78(涨约9.6%)、收34.38涨8.32%，成交12.08亿港元、量比4.28倍，主市场当日已完成重定价市场反应:3692.HK +8.32%，放量4.28倍，市值2085亿港元
- 本信号为美东盘中对隔夜已公开明牌的延迟转述；HNSPF粉单4.25美元无成交
关键理由
- 4亿美元首付+1.1亿美元周年款(约合40亿港元级现金)对翰森是实质增量，且验证其ADC平台全球竞争力——但该逻辑已于10月20日单日涨8.32%计入股价
主要风险
- 明牌利好次日易高开低走，155亿美元里程碑高度或有、与后续研发/审批/销售挂钩，短期估值兑现后存在获利回吐压力
- 若次日开盘继续高开，追高风险收益比差；港股T+0但无涨跌停，隔夜缺口不可控
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
155亿美元为开发/审批/销售挂钩的高度或有里程碑，非确定收入；确定现金仅约5.1亿美元，且股价已单日涨8.32%、逼近盘中高点回落，继续追高的赔率差
检索:翰森制药 罗氏 ADC 10月20日 涨幅 目标价 风险 里程碑 或有 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持以PRICE_IN回避：唯一实质标的已当日兑现，次日追高的期望为负
方向:未在本轮构建可对齐先例面板
涨幅量级:不足：本信号到达时核心催化已在唯一流动性主市场(港股)以放量+8.32%单日完成定价，是否追高的关键变量是次日开盘承接而非历史授权交易平均涨幅，再补先例对决策无增量
形态:经验库中A股/港股盘后明牌利好次日竞价追高胜率偏低(PF<1)、多见高开低走，支持不追高
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`hansoh pharmaceutical roche adc licensing agreement $400 million upfront | 翰森制药 roche 150亿美元 milestones adc | 翰森制药 罗氏 adc 合作 授权 4亿美元 首付款`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研 - web_search 成功 doubao_search · 1,574 ms
豆包搜索结果（原始查询:Hansoh Pharmaceutical Roche ADC deal $400 million upfront $15 billion milestones；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 2,982 ms
{
原文全文
展开原文 · 2,636 字
Hansoh Pharmaceutical Group Co., Ltd. (HNSPF), a China-based pharmaceutical company, has entered into a strategic collaboration and licensing agreement with Roche Holding AG (RHHBY) to advance a broad portfolio of antibody-drug conjugate (ADC) programs targeting multiple cancer types.
Under the agreement, Hansoh is eligible to receive an upfront payment of $400 million, a first-anniversary payment of $110 million and potentially more than $15 billion in milestone payments tied to development, regulatory approvals and commercialization. The deal also includes tiered royalties on potential future product sales.
The collaboration covers two preclinical ADC programs developed by Hansoh and multiple programs based on targets proposed by Roche, using Hansoh's proprietary ADC technology platform.
Hansoh will lead early development through completion of global Phase 1a clinical trials. Roche will oversee subsequent worldwide development and commercialization, excluding mainland China, Hong Kong, Macau and Taiwan. Hansoh will retain development and commercialization rights in those territories.
Hansoh also has the option to select up to two programs and contribute to their development outside the specified Chinese territories, potentially receiving additional commercial benefits from sales of those programs in the United States.
The agreement marks the second ADC collaboration between Hansoh and Roche, building on their existing partnership to accelerate the development of next-generation cancer therapies.
Hansoh said the collaboration supports its strategy of leveraging its ADC expertise and technology platform to advance innovative oncology treatments for patients worldwide.
Roche said the expanded partnership will help explore next-generation ADCs and address unmet medical needs in cancer care.
The financial terms include potential milestone payments exceeding $15 billion, although these payments are contingent on the programs achieving specified development, regulatory and commercial milestones. Future royalties will depend on potential product sales.
RHHBY is currently trading at $58.86, up 3.01%.
HNSPF's stock closed trading at $4.25 without any movement on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
Under the agreement, Hansoh is eligible to receive an upfront payment of $400 million, a first-anniversary payment of $110 million and potentially more than $15 billion in milestone payments tied to development, regulatory approvals and commercialization. The deal also includes tiered royalties on potential future product sales.
The collaboration covers two preclinical ADC programs developed by Hansoh and multiple programs based on targets proposed by Roche, using Hansoh's proprietary ADC technology platform.
Hansoh will lead early development through completion of global Phase 1a clinical trials. Roche will oversee subsequent worldwide development and commercialization, excluding mainland China, Hong Kong, Macau and Taiwan. Hansoh will retain development and commercialization rights in those territories.
Hansoh also has the option to select up to two programs and contribute to their development outside the specified Chinese territories, potentially receiving additional commercial benefits from sales of those programs in the United States.
The agreement marks the second ADC collaboration between Hansoh and Roche, building on their existing partnership to accelerate the development of next-generation cancer therapies.
Hansoh said the collaboration supports its strategy of leveraging its ADC expertise and technology platform to advance innovative oncology treatments for patients worldwide.
Roche said the expanded partnership will help explore next-generation ADCs and address unmet medical needs in cancer care.
The financial terms include potential milestone payments exceeding $15 billion, although these payments are contingent on the programs achieving specified development, regulatory and commercial milestones. Future royalties will depend on potential product sales.
RHHBY is currently trading at $58.86, up 3.01%.
HNSPF's stock closed trading at $4.25 without any movement on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a365de1fb1· 2026-10-20 23:55 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前